[Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]

Area of Science:

• Cardiovascular Medicine
• Inflammation Research
• Pharmacology

Background:

• Atherosclerosis is an inflammatory disease where both lipids and inflammation are key targets.
• Targeting inflammation, as shown by the CANTOS trial with canakinumab, can reduce cardiovascular risk.
• Previous anti-inflammatory drugs like methotrexate have not demonstrated cardiovascular benefits.

Purpose of the Study:

• To evaluate the efficacy of colchicine, a non-selective inflammasome inhibitor, in reducing cardiovascular events.
• To assess the role of anti-inflammatory therapy in managing cardiovascular risk beyond lipid management.

Main Methods:

• The COLCOT trial investigated colchicine's effect in acute myocardial infarction patients.
• The LoDoCo2 trial confirmed these findings in stable coronary heart disease patients.
• Both trials focused on ischemic cardiovascular events as primary endpoints.

Main Results:

• The COLCOT trial demonstrated a significant reduction in ischemic cardiovascular events.
• The LoDoCo2 trial corroborated the cardiovascular benefits of colchicine in a larger cohort.
• Colchicine showed efficacy in reducing cardiovascular risk in different coronary heart disease populations.

Conclusions:

• Colchicine has proven effective in reducing cardiovascular events in patients post-myocardial infarction and in stable coronary heart disease.
• These findings suggest colchicine could become a routine anti-inflammatory treatment for cardiovascular risk management.
• Guideline committees will consider this evidence for incorporating colchicine into cardiovascular guidelines.